Exposure-Response Analysis of Etrolizumab in Patients with Moderately-to-severely Active Ulcerative Colitis ACoP12 (Nov 2021) PMX-82. Kassir N, Zhu R, Moein A, Langenhorst J, Ribbing J, Zhang R, Tang M, Oh YS, Zhang W. ConferenceImmunologyInflammationPharmacometrics Pharmetheus Affiliates Senior Consultant & Team Leader Jurgen Langenhorst See bio Principal Consultant & Client Operations Expert Jakob Ribbing See bio
